93 related articles for article (PubMed ID: 21611090)
21. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy for pancreatic cancer.
Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
[TBL] [Abstract][Full Text] [Related]
23. Personalization of chemotherapy for metastatic pancreatic cancer.
Sasahara YI; Narimatsu H; Suzuki S; Fukui T; Sato H; Shirahata N; Yoshioka T
Clin Med Insights Case Rep; 2014; 7():59-61. PubMed ID: 25093005
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Takahara N; Satoh Y; Takai D; Kogure H; Yamamoto N; Hirano K; Tada M; Yatomi Y; Koike K
Anticancer Res; 2013 Jun; 33(6):2619-22. PubMed ID: 23749917
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H; Ioka T; Ikeda M; Ohkawa S; Yanagimoto H; Boku N; Fukutomi A; Sugimori K; Baba H; Yamao K; Shimamura T; Sho M; Kitano M; Cheng AL; Mizumoto K; Chen JS; Furuse J; Funakoshi A; Hatori T; Yamaguchi T; Egawa S; Sato A; Ohashi Y; Okusaka T; Tanaka M
J Clin Oncol; 2013 May; 31(13):1640-8. PubMed ID: 23547081
[TBL] [Abstract][Full Text] [Related]
26. Intestinal Flora in Chemotherapy Resistance of Biliary Pancreatic Cancer.
Bai L; Yan X; Lv J; Qi P; Song X; Zhang L
Biology (Basel); 2023 Aug; 12(8):. PubMed ID: 37627035
[TBL] [Abstract][Full Text] [Related]
27. Stent-in-Stent for Malign Obstruction: Should We Go Back to a Place Where We Were Happy?
Baldaque-Silva F
GE Port J Gastroenterol; 2020 Nov; 27(6):375-377. PubMed ID: 33251285
[No Abstract] [Full Text] [Related]
28. Clinical outcomes after multiple self-expandable metallic stent placement using stent-in-stent technique for malignant gastric outlet obstruction.
Mo JW; Kim YM; Kim JH; Shin SY; Youn YH; Park H
Medicine (Baltimore); 2020 May; 99(21):e19432. PubMed ID: 32481247
[TBL] [Abstract][Full Text] [Related]
29. Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Ito Y; Yasuda I; Toda N; Yagioka H; Matsubara S; Hanada K; Maguchi H; Kamada H; Hasebe O; Mukai T; Okabe Y; Maetani I; Koike K
World J Gastroenterol; 2014 Dec; 20(48):18452-7. PubMed ID: 25561816
[TBL] [Abstract][Full Text] [Related]
30. Enteral stents are safe and effective to relieve malignant gastric outlet obstruction in the elderly.
Mansoor H; Zeb F
J Gastrointest Cancer; 2015 Mar; 46(1):42-7. PubMed ID: 25487197
[TBL] [Abstract][Full Text] [Related]
31. A novel, fully covered laser-cut nitinol stent with antimigration properties for nonresectable distal malignant biliary obstruction: a multicenter feasibility study.
Isayama H; Kawakubo K; Nakai Y; Inoue K; Gon C; Matsubara S; Kogure H; Ito Y; Tsujino T; Mizuno S; Hamada T; Uchino R; Miyabayashi K; Yamamoto K; Sasaki T; Yamamoto N; Hirano K; Sasahira N; Tada M; Koike K
Gut Liver; 2013 Nov; 7(6):725-30. PubMed ID: 24312715
[TBL] [Abstract][Full Text] [Related]
32. Current status of chemotherapy for the treatment of advanced biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Koike K
Korean J Intern Med; 2013 Sep; 28(5):515-24. PubMed ID: 24009445
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective study.
Mansoor H; Yusuf MA
BMC Res Notes; 2013 Jul; 6():280. PubMed ID: 23870091
[TBL] [Abstract][Full Text] [Related]
34. Improvement of prognosis for unresectable biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Takahara N; Sasahira N; Kogure H; Mizuno S; Yagioka H; Ito Y; Yamamoto N; Hirano K; Toda N; Tada M; Omata M; Koike K
World J Gastroenterol; 2013 Jan; 19(1):72-7. PubMed ID: 23326165
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for the biliary tract cancers: moving toward improved survival time.
Romiti A; D'Antonio C; Zullo A; Sarcina I; Di Rocco R; Barucca V; Durante V; Marchetti P
J Gastrointest Cancer; 2012 Sep; 43(3):396-404. PubMed ID: 22328060
[TBL] [Abstract][Full Text] [Related]
36. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Nam HJ; Kim HP; Yoon YK; Song SH; Min AR; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Invest New Drugs; 2012 Dec; 30(6):2148-60. PubMed ID: 22197904
[TBL] [Abstract][Full Text] [Related]
37. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers.
Tada M; Nakai Y; Sasaki T; Hamada T; Nagano R; Mohri D; Miyabayashi K; Yamamoto K; Kogure H; Kawakubo K; Ito Y; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Isayama H; Omata M; Koike K
World J Clin Oncol; 2011 Mar; 2(3):158-63. PubMed ID: 21611090
[TBL] [Abstract][Full Text] [Related]
38. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
39. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.
Park SJ; Kim H; Shin K; Lee MA; Hong TH
World J Gastrointest Oncol; 2019 Nov; 11(11):1021-1030. PubMed ID: 31798782
[TBL] [Abstract][Full Text] [Related]
40. Genomics and pharmacogenomics of pancreatic adenocarcinoma.
Lowery MA; O'Reilly EM
Pharmacogenomics J; 2012 Feb; 12(1):1-9. PubMed ID: 22186617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
